27573-97-3

Usage

Structure

A piperidine derivative with a benzyl group and a hydroxyethyl group attached to the piperidine ring

Usage

a. Intermediate in the synthesis of pharmaceuticals and other organic compounds
b. Potential pharmacological properties for the treatment of various medical conditions
c. Evaluation for the synthesis of novel drug candidates
d. Industrial applications

Properties

a. Chemical compound
b. Contains a benzyl group and a hydroxyethyl group
c. Used in the pharmaceutical industry
d. Studied for potential medical applications

InChI:InChI=1/C14H21NO2/c16-11-8-14(17)6-9-15(10-7-14)12-13-4-2-1-3-5-13/h1-5,16-17H,6-12H2

Upstream product

• 67281-07-6 ethyl 2-(1-benzyl-4-hydroxypiperidin-4-yl)acetate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 6938-07-4 N,N-bis(2-ethoxycarbonylethyl)benzylamine 
• 50-00-0 formaldehyd 
• 90284-71-2 N-benzylammonium trifluoroacetate 
• 86341-37-9 3-(Trimethylsilanylmethyl)but-3-en-1-ol 

Downstream Products

• 67281-04-3 9-benzyl-1,3-dioxa-9-aza-spiro[5.5]undecane 
• 67281-18-9 9-benzyl-2-phenyl-1,3-dioxa-9-aza-spiro[5.5]undecane 
• 67281-16-7 9-benzyl-2-methyl-1,3-dioxa-9-aza-spiro[5.5]undecane 
• 1445796-13-3 C₂₀H₃₅NO₂Si 
• 1374856-41-3 C₁₅H₂₃NO₂ 
• 1374855-95-4 (E)-3-(4-chlorophenyl)-N-(2-(4-hydroxy-4-(2-methoxyethyl)piperidin-1-yl)-4-methylquinazolin-6-yl)acrylamide 
• 1374855-94-3 (E)-3-(4-chlorophenyl)-N-(2-(4-hydroxy-4-(2-hydroxyethyl)piperidin-1-yl)-4-methylquinazolin-6-yl)acrylamide 
• 109187-97-5 1-benzyl-4-bromo-quinuclidinium; bromide 
• 55023-26-2 1-benzyl-4-hydroxy-quinuclidinium; toluene-4-sulfonate 

Relevant academic research and scientific papers

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: Part 2

Melanin concentrating hormone receptor 1 (MCHR1) antagonists have potential for the treatment of obesity and several CNS disorders. In the preceding article, we have described a novel series of quinazolines as MCHR1 antagonists and demonstrated in vivo proof of principle with an early lead. Herein we describe the detailed SAR and SPR studies to identify an optimized lead candidate having good efficacy in a sub-chronic DIO model with a good cardiovascular safety window.